Tomorrow, March, 22, 2022, the FDA will host a public meeting entitled “Final Assessment of the Program for Enhanced Review Transparency and Communication in in the Biosimilar User Fee.
Tomorrow, March, 22, 2022, the FDA will host a public meeting entitled "Final Assessment of the Program for Enhanced Review Transparency and Communication in in the Biosimilar User Fee Act."